Digital health · 2026
A targeted behavioral economics-based mobile health intervention to improve medication adherence in patients with hypertension: A three-arm randomized controlled trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Strebel Jan, Raja Beharelle Anjali, Mayr Michael, Nemtsova Valeriya, Zahnd Joachim, Wuerzner Gregoire, Ehret Georg, Stiefel Michael, Rexhaj Emrush, Meister Théo, Vischer Annina S, Burkard Thilo
Аннотация
BACKGROUND: Non-adherence to antihypertensive therapy remains a major barrier to optimal blood pressure (BP) control. This study evaluated whether a multi-faceted medication adherence mobile application (mApp), with or without financial incentives (FI), improves adherence and BP compared with standard care.
METHODS: In this multicenter, randomized, open-label trial, outpatients with hypertension taking ≥4 pills/day were randomized to (A) mApp with FI, (B) mApp without FI, or (C) standard-of-care. Adherence was measured by Medication Event Monitoring System (MEMS) dispensers. Primary endpoint was median adherence at 90 days comparing A with C; the co-primary endpoint compared adherence during month 3 versus month 1. Secondary outcomes included self-reported adherence, office and ambulatory BP over 90 and 180 days.
RESULTS: Of 219 randomized participants, 176 (80.4%) completed the 90-day visit (median age 63 years; 23% women). Median adherence at 90 days was 95.6% in A and C (p=0.551). Median change in adherence from month 1 to month 3 was 0% in A and 1.6% in C (p=0.691). No significant differences were observed for BP. Self-reported adherence did not differ between groups, although within-group analyses showed improvement over time in A (p=0.001).
CONCLUSIONS: In outpatients with hypertension and unexpectedly high observed adherence and no substantial BP elevation at baseline, neither the mApp nor FI improved MEMS-measured adherence or BP. Future interventions should focus on identifying and engaging patients with low medication adherence and sufficient room for BP improvement, for whom digital strategies may have greater impact.
METHODS: In this multicenter, randomized, open-label trial, outpatients with hypertension taking ≥4 pills/day were randomized to (A) mApp with FI, (B) mApp without FI, or (C) standard-of-care. Adherence was measured by Medication Event Monitoring System (MEMS) dispensers. Primary endpoint was median adherence at 90 days comparing A with C; the co-primary endpoint compared adherence during month 3 versus month 1. Secondary outcomes included self-reported adherence, office and ambulatory BP over 90 and 180 days.
RESULTS: Of 219 randomized participants, 176 (80.4%) completed the 90-day visit (median age 63 years; 23% women). Median adherence at 90 days was 95.6% in A and C (p=0.551). Median change in adherence from month 1 to month 3 was 0% in A and 1.6% in C (p=0.691). No significant differences were observed for BP. Self-reported adherence did not differ between groups, although within-group analyses showed improvement over time in A (p=0.001).
CONCLUSIONS: In outpatients with hypertension and unexpectedly high observed adherence and no substantial BP elevation at baseline, neither the mApp nor FI improved MEMS-measured adherence or BP. Future interventions should focus on identifying and engaging patients with low medication adherence and sufficient room for BP improvement, for whom digital strategies may have greater impact.